Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
City of Hope Medical Center
Thomas Jefferson University
H. Lee Moffitt Cancer Center and Research Institute
Penn State University
City of Hope Medical Center
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Brown University
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
City of Hope Medical Center
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
Seattle Children's Hospital
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
Scripps Translational Science Institute
M.D. Anderson Cancer Center
Washington University School of Medicine
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
City of Hope Medical Center
Thomas Jefferson University
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
Thomas Jefferson University
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
M.D. Anderson Cancer Center
City of Hope Medical Center
Therapeutic Advances in Childhood Leukemia Consortium
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
University of Nebraska
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
Therapeutic Advances in Childhood Leukemia Consortium